OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Ciombor Discusses Role of Liquid Biopsies in CRC

April 22nd 2019

Kristen Ciombor, MD, MSCI, assistant professor of medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, discusses the role of liquid biopsies in colorectal cancer.

Dr. LaCasce Discusses the Future of MCL Treatment

April 22nd 2019

Ann S. LaCasce, MD, MMSc, director of Dana-Farber/Partners CancerCare Hematology-Medical Oncology Fellowship Program, institute physician, Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School, discusses the future of mantle cell lymphoma treatment.

Dr. Figlin on Promise of Immunotherapy Plus TKI Combinations in RCC

April 22nd 2019

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses the promise of immunotherapy plus TKI combinations in the treatment of patients with renal cell carcinoma.

Dr. Powles on FDA Approval of Pembrolizumab Plus Axitinib in Advanced RCC

April 22nd 2019

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses the FDA approval of the combination of pembrolizumab (Keytruda) plus axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma (RCC).

Dr. Fenske Discusses Disease Progression on Ibrutinib in MCL

April 21st 2019

Timothy Fenske, MD, MS, an associate professor at the Medical College of Wisconsin, discusses his recommendations for oncologists treating patients with mantle cell lymphoma (MCL) who are progressing on ibrutinib (Imbruvica).

Dr. Quinn on Current State of Biomarkers in RCC

April 19th 2019

David I. Quinn, MD, PhD, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, Keck School of Medicine, discusses the current state of biomarkers in renal cell carcinoma.

Dr. Overman on Unmet Needs With Immunotherapy in mCRC

April 19th 2019

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses unmet needs with immunotherapy in metastatic colorectal cancer.

Dr. Shah on Challenges With Developing MCL Clinical Trials

April 19th 2019

Bijal D. Shah, MD, associate member, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses challenges with developing mantle cell lymphoma clinical trials.

Dr. Duncan on the Use of CAR T-Cell Therapy in Pediatric ALL

April 19th 2019

Christine N. Duncan, MD, senior physician, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the use of CAR T-cell therapy in the treatment of pediatric patients with acute lymphocytic leukemia (ALL).

Dr. Agarwal on Updated Results of the JAVELIN Renal 101 Trial in Advanced RCC

April 19th 2019

Neeraj Agarwal, MD, professor of medicine, physician and investigator, director, Genitourinary Oncology Program, Center of Investigational Therapeutics, Huntsman Cancer Institute, University of Utah, discusses the updated results of the JAVELIN Renal 101 trial in advanced renal cell carcinoma (RCC).

Dr. Gomella on the Prevalence of Genetic Testing in Prostate Cancer

April 19th 2019

Leonard G. Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the prevalence of genetic testing in prostate cancer.

Dr. Usmani on Treatment of Newly Diagnosed Myeloma

April 18th 2019

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses the treatment of patients with newly diagnosed myeloma.

Dr. Konduri on Sequencing Therapy in EGFR+ NSCLC

April 18th 2019

Kartik Konduri, MD, co-medical director of the Lung Cancer Center of Excellence, Baylor Charles A. Sammons Cancer Center, on the campus of Baylor University Medical Center, discusses sequencing therapy in patients with EGFR-positive non–small cell lung cancer.

Dr. Goy on Treatment Considerations in MCL

April 18th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses treatment considerations in mantle cell lymphoma.

Dr. Mansfield Discusses Challenges in SCLC

April 18th 2019

Aaron S. Mansfield, MD, associate professor of oncology, consultant in the Division of Medical Oncology, Mayo Clinic, discusses challenges in the treatment of patients with small cell lung cancer.

Dr. Raje Compares Data for Triplet Regimens in Myeloma

April 18th 2019

Noopur Raje, MD, professor of medicine at Harvard Medical School and director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center, discusses data for the standard triplet regimens in the treatment of patients with relapsed/refractory myeloma.

Dr. Tempero on Role of Molecular Profiling in Pancreatic Cancer

April 18th 2019

Margaret A. Tempero, MD, director, University of California, San Francisco (UCSF) Pancreas Center, professor of medicine, Division of Hematology and Oncology, Rombauer Family Distinguished Professor in Pancreas Cancer Clinical and Translational Science, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the role of molecular profiling in pancreatic cancer.

Dr. LaCasce on Key Advances in the MCL Paradigm

April 18th 2019

Dr. Antonarakis on Implications of an MMR Deficiency in Prostate Cancer

April 18th 2019

Emmanuel S. Antonarakis, MD, associate professor of oncology, Johns Hopkins University, discusses the clinical implications of an MMR deficiency in patients with prostate cancer.

Dr. Fakih on Immunotherapy in MSS Colon Cancer

April 18th 2019

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses the use of immunotherapy in patients with microsatellite stable (MSS) colon cancer.